SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Elder Pharma gains on unveiling Zalain in association with Ferrer

06 Jun 2012 Evaluate

Elder Pharmaceuticals is currently trading at Rs. 305.50, up by 2.85 points or 0.94% from its previous closing of Rs. 302.65 on the BSE.

The scrip opened at Rs. 307.70 and has touched a high and low of Rs. 310.00 and Rs. 301.55 respectively. So far 9,240 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 435.00 on 29-Jul-2011 and a 52 week low of Rs. 291.20 on 01-Jun-2012.

Last one week high and low of the scrip stood at Rs. 318.00 and Rs. 291.20 respectively. The current market cap of the company is Rs. 627.00 crore.

The promoters holding in the company stood at 39.60% while Institutions and Non-Institutions held 24.76% and 35.65% respectively.

Elder Pharmaceuticals in association with Spain-based drug firm Ferrer has unveiled -- Zalain -- a medicine used to treat fungal skin infections, in India. The company has launched the same to strengthen its anti-infectives division which stood at about Rs 113.61 crore in FY 2012

The company, to strengthen position in the segment in domestic market, has also lined-up five more launches of nutraceutical products in India in partnerships with international firms in the coming six months.

At present, the company markets various nutraceutical products in the country, including calcium supplement -- Shelcal. Its product portfolio comprises licensed as well as own brands.

Elder Pharmaceuticals posted 15.46% fall in its consolidated net profit at Rs 14.60 crore for the quarter ended March 31, 2012 as compared to Rs 17.27 crore in the corresponding period of previous fiscal. The fall is mainly on account of reduction in material costs.

Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×